COVID-19: which monoclonal antibodies should be used for vulnerable individuals?

Vaccination does not offer sufficient protection against severe forms of COVID-19 for people with a weakened immune system. For these individuals, monoclonal antibodies have long been the preferred therapeutic solution. But depending on the SARS-CoV-2 variant, the effectiveness of these treatments has fluctuated. Scientists have had to develop novel antibodies that are more effective while also regularly evaluating those already in use. An Institut Pasteur team has been helping healthcare providers to determine the most suitable treatment strategies for their patients.

The Communications and Public Affairs Department looked at how a team from Institut Pasteur helped caregivers in several French hospitals to determine the most appropriate treatment strategies for patients with severe covid during the pandemic. Indeed, at the heart of the Virus and Immunity team's work on Covid-19, cooperation with clinical partners is essential. These include the CHR Orléans, the Hôpital Européen Georges-Pompidou, the Hôpital Universitaire de la Pitié-Salpêtrière and the CHU de Toulouse. Moreover, monoclonal antibodies are still a highly topical therapeutic solution. Research is continuing into the production of new, more effective monoclonal antibodies, for example with the start-up SpikImm.
 

See the video explaining this subject for the general public

Find out more